Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.

J Rheumatol

From the Université Paris-Descartes; APHP, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares, service de médecine interne, Paris; Service de médecine interne, Centre hospitalier d'Abbeville, Abbeville; Service de médecine interne, Université Grenoble Alpes, Centre Hospitalier Universitaire (CHU) de Grenoble, Grenoble; Service de médecine interne, Centre Hospitalier Général de Mulhouse, Mulhouse; Service de médecine interne, CHU de Limoges, Limoges; Department of Rheumatology, Hôpital Cochin, APHP; INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité, Paris; Service de médecine interne, Hôpital Avicenne, Bobigny; Service de médecine interne, Hôpital Hôtel-Dieu, Nantes; Service de rhumatologie, CHU de Clermont-Ferrand, Clermont Ferrand; Service de médecine interne et médecine polyvalente, Hôpital de Saint Quentin, Saint Quentin; Service de médecine interne, CH de Dax, Dax; Service de médecine interne, Hôpital Claude Huriez, Lille; Centre d'Investigation Clinique Biothérapie INSERM CIC-1431, FHU INCREASE, Service de rhumatologie, Centre Hospitalier Régional Universitaire (CHRU), Besançon, France.A. Régent, MD, PhD, Université Paris-Descartes; APHP, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares, service de médecine interne; S. Redeker, MD, Service de médecine interne, Centre hospitalier d'Abbeville; A. Deroux, MD, Service de médecine interne, Université Grenoble Alpes, CHU de Grenoble; P. Kieffer, MD, Service de médecine interne, Centre Hospitalier Général de Mulhouse; K.H. Ly, MD, PhD, Service de médecine interne, CHU de Limoges; M. Dougados, MD, PhD, Université Paris-Descartes, Department of Rheumatology, APHP, Hôpital Cochin, INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité; E. Liozon, MD, Service de médecine interne, CHU de Limoges; C. Larroche, MD, Service de médecine interne, Hôpital Avicenne;

Published: August 2016

Objective: To report the efficacy and safety of tocilizumab (TCZ) for giant cell arteritis (GCA).

Methods: A retrospective multicenter study that included 34 patients receiving TCZ for GCA.

Results: TCZ was effective in all but 6 patients, who still had mild symptoms. Mean glucocorticoid dose was tapered. One patient died and 3 patients had to stop TCZ therapy because of severe adverse events. Twenty-three patients stopped treatment; 8 of these experienced relapses after a mean of 3.5 ± 1.3 months.

Conclusion: TCZ is effective in GCA. However, side effects occur. Whether this treatment has only a suspensive effect remains to be determined.

Download full-text PDF	Source
http://dx.doi.org/10.3899/jrheum.151252	DOI Listing

Publication Analysis

Top Keywords

giant cell

cell arteritis

tcz effective

patients

tcz

tocilizumab giant

arteritis multicenter

multicenter retrospective

retrospective study

study patients

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!